Ipilimumab
From Ganfyd
rINN: Ipilimumab
Other Names
MDX-010, MDX-101
Pharmacological Information
Ipilimumab in the:
BNF-registration required
BNF for children-registration required
Relevant Clinical Literature
Systematic reviews from Pubmed
Other Literature
Please read pharmacological data limitations
Monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4). The interaction of CTLA-4 with its corresponding ligand exerts a negative effect of T-cell activity. CTLA-4 is an inducible receptor expressed by T cells which binds mainly CD80 or CD86 (B7-family of molecules) on antigen-presenting cells. Blockage of this interaction is therefore thought to enhance cell-mediated immunity.
It has been used experimentally as an immunomodulatory agent in advanced cancers, including prostatic adenocarcinoma and melanoma.[1]
Side effects
Mainly immune-related adverse events such as colitis and rash which are predictive of response..
- Refractory colitis[2]
- Neutropenia
- Hypophysitis[3] with refractory panhypopituitarism
- Short-term tumor progression
References
- ↑ O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007 Dec 15; 110(12):2614-27.(Link to article – subscription may be required.)
- ↑ Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB. Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3(+) T Cells. Digestive diseases and sciences. 2009 Jun 9.(Epub ahead of print) (Link to article – subscription may be required.)
- ↑ Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-Induced Hypophysitis: MR Imaging Findings. AJNR. American journal of neuroradiology. 2009 May 27.(Epub ahead of print) (Link to article – subscription may be required.)
